Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.
about
A validated model of serum anti-müllerian hormone from conception to menopauseThe anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligandAnimal models of ovarian cancerRole of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a reviewRegulation of the ovarian reserve by members of the transforming growth factor beta familySmad1-Smad5 ovarian conditional knockout mice develop a disease profile similar to the juvenile form of human granulosa cell tumors.AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapyDeletion of tuberous sclerosis 1 in somatic cells of the murine reproductive tract causes female infertility.Loss of inhibin alpha uncouples oocyte-granulosa cell dynamics and disrupts postnatal folliculogenesis.Conditional deletion of the retinoblastoma (Rb) gene in ovarian granulosa cells leads to premature ovarian failure.The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.The regulatory role of Dicer in folliculogenesis in mice.FSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells.Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells.Effect of anti-Mullerian hormone in culture medium on quality of mouse oocytes matured in vitroSerum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenismRoles for transforming growth factor beta superfamily proteins in early folliculogenesis.Distribution and responsiveness of rat anti-Müllerian hormone during ovarian development and VCD-induced ovotoxicity.Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumorsAnti-Müllerian hormone plasma concentration in prepubertal ewe lambs as a predictor of their fertility at a young age.Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome.The physiology and clinical utility of anti-Mullerian hormone in women.Anti-Müllerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by ART cycles?Oocyte-somatic cells interactions, lessons from evolution.A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier StateChanges in plasma müllerian-inhibiting substance and brain-derived neurotrophic factor after chemotherapy in premenopausal womenThe correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile womenAnti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatmentRegulation of gonadotropin gene expression by Mullerian inhibiting substance.Loss of gremlin delays primordial follicle assembly but does not affect female fertility in miceIn vitro follicle growth under non-attachment conditions and decreased FSH levels reduces Lhcgr expression in cumulus cells and promotes oocyte developmental competenceWilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.Effects of GnRH agonists on the expression of developmental follicular anti-mullerian hormone in varying follicular stages in cyclic mice in vivo.Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing.The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments.Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism.Serum anti-müllerian hormone, follicle stimulating hormone and antral follicle count measurement cannot predict pregnancy rates in IVF/ICSI cycles.The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signalingFollicular fluid hormonal profile and cumulus cell gene expression in controlled ovarian hyperstimulation with recombinant FSH: effects of recombinant LH administration.Technical challenges and limitations of current mouse models of ovarian cancer.
P2860
Q21135308-CA1B1A3A-D103-4751-B97E-AA8D5B90C4D5Q24306670-89026DD9-A1FB-410F-8AB6-597828988633Q24791470-C1CCFB44-CB3C-4FFD-9587-B31224F2891CQ26774060-A10C5AD8-7207-47F8-9471-482C034CA8F8Q26996828-1BB631C0-1FEA-459A-B595-D7D01216D363Q30040477-236FA903-F8CF-48B6-9FFF-EA676492E7B0Q30353654-73D03F8A-0727-4831-931C-B492484065DFQ30423103-4610D19E-F22C-4978-866D-0263893BD9D0Q30434519-6973D17A-59AB-4811-A909-88971D6C8046Q30438817-FAE1226B-6150-4E07-A613-A9087EDB546EQ33569721-5CF190C0-EB63-4553-814E-1E60A43B2DDBQ33624124-6C60B141-2E56-4FD2-9D21-76FA3A08A9F8Q33636964-55C1F133-222B-4A94-A631-20158181D4D5Q33682524-2DC4CB00-BB6A-4083-9C90-62E210EADA28Q33763232-6A8E0CF7-D9B5-4EF4-9022-123DDED47455Q33786859-F6F0A801-DD98-4125-80D0-652705FFDCC5Q34161992-9A85AAA7-2BFD-4AF4-8337-D0CC4324AD93Q34209380-051363FC-782D-4222-AD26-DFB0306490B7Q34246272-8B6956B3-70F7-474D-8FEC-8D69FD0A8443Q34348167-3516DA6B-059A-4D16-9EAB-8CAD1F1B614FQ34363167-BD647DF7-9EAE-41C0-819E-384459DD0241Q34398233-D5886DA5-1B99-476E-8A3C-10D5DF70DABFQ34415976-F23B2917-3BB8-4260-B913-FB2ED3DF1A19Q34452883-3246DA0A-5E33-44F6-BB71-393BABBDD171Q34503833-55F47DEB-966B-4040-835F-0B83D4A44D7BQ34618818-7FBD7C09-2FB2-48C1-8A36-69B7BFBC50E0Q35166382-6BAC4626-C7FB-42C9-B134-DD460E832CEDQ35171104-702C0274-DA49-4A9C-8209-B67C38D07DEBQ35234562-349EED80-A942-4DF1-BFB2-FB2A4613108EQ35570723-0BB04265-B10D-4E74-8F7D-AF1FF17278C1Q35722678-0B069D0C-73A4-4132-A917-8A54B8BAF6C5Q35857103-4A6F7350-2B78-4E12-B9CF-4E7A88EE032EQ35919719-9AA52966-1C67-4780-85ED-349A4E07E3DAQ35966481-31776FC9-BDA6-4AC7-B69C-D8CA3CE9D970Q35976287-93BD91BC-7328-4CA7-872B-83E0392FDAA7Q36106370-C72383C2-F9D2-42C3-BFD0-1F24D1461086Q36106435-B2236EFD-CEDF-4C54-BBF1-7F1DBED303F2Q36435768-BC36D38D-D2A2-4C61-BF3B-6CA39BFF4379Q36484614-E4300B01-E0EB-49F8-8E8A-396251C73F7EQ36510070-EE84AF02-0DED-4B40-92DB-5C92AEF659A0
P2860
Anti-müllerian hormone and anti-müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@en
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@nl
type
label
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@en
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@nl
prefLabel
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@en
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@nl
P2093
P1433
P1476
Anti-müllerian hormone and ant ...... ropin-induced follicle growth.
@en
P2093
Baarends WM
Grootegoed JA
Hoogerbrugge JW
Themmen AP
Uilenbroek JT
van Leeuwen EC
P304
P356
10.1210/ENDO.136.11.7588229
P407
P577
1995-11-01T00:00:00Z